Antiplatelet agents for chronic kidney disease
CONCLUSIONS: Antiplatelet agents probably reduced myocardial infarction and increased major bleeding, but do not appear to reduce all-cause and cardiovascular death among people with CKD and those treated with dialysis. The treatment effects of antiplatelet agents compared with each other are uncertain.PMID:35224730 | DOI:10.1002/14651858.CD008834.pub4
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Patrizia Natale Suetonia C Palmer Valeria M Saglimbene Marinella Ruospo Mona Razavian Jonathan C Craig Meg J Jardine Angela C Webster Giovanni Fm Strippoli Source Type: research
More News: Abciximab | Bleeding | Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Clopidogrel | Conferences | Databases & Libraries | Dialysis | General Medicine | Heart | Heart Attack | Hemodialysis | Kidney Transplant | Kidney Transplantation | Plavix | Proteinuria | Stroke | Study | Thrombosis | Transplant Surgery | Transplants | Urology & Nephrology